CIT - citron rho-interacting serine/threonine kinase Gene
Species: Bos taurus
Gene Type: protein coding
Gene ID: 786852
CIT Products (12)
| mRNA | Protein | Name |
|---|---|---|
| XM_024977733.1 | XP_024833501.1 | citron Rho-interacting kinase isoform X1 |
| XM_024977735.1 | XP_024833503.1 | citron Rho-interacting kinase isoform X2 |
| XM_024977736.1 | XP_024833504.1 | citron Rho-interacting kinase isoform X3 |
| XM_024977737.1 | XP_024833505.1 | citron Rho-interacting kinase isoform X4 |
| XM_024977738.1 | XP_024833506.1 | citron Rho-interacting kinase isoform X5 |
| XM_024977741.1 | XP_024833509.1 | citron Rho-interacting kinase isoform X8 |
| XM_024977734.1 | XP_024833502.1 | citron Rho-interacting kinase isoform X1 |
| XM_024977739.1 | XP_024833507.1 | citron Rho-interacting kinase isoform X6 |
| XM_024977740.1 | XP_024833508.1 | citron Rho-interacting kinase isoform X7 |
| XM_024977743.1 | XP_024833511.1 | citron Rho-interacting kinase isoform X9 |
| XM_024977742.1 | XP_024833510.1 | citron Rho-interacting kinase isoform X9 |
| XM_024977744.1 | XP_024833512.1 | citron Rho-interacting kinase isoform X10 |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
citron Rho-interacting kinase |
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(2)
| Referencia número | Nombre del producto |
Efecto
|
Pureza |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9985 | Disitamab vedotin | Inhibitor | 99.06% | Unkown |
| HY-P99016A | Enfortumab vedotin-ejfv | Inhibitor | 99.69% | Unkown |
Clinical Phase
Bioactive Molecules
(4)
| Referencia número | Nombre del producto |
Efecto
|
Pureza |
Phase |
|---|---|---|---|---|
| HY-160441 | MC-Val-Cit-PAB-Ispinesib | Inhibitor | 99.85% | Phase 3 |
| HY-P99612 | Farletuzumab ecteribulin | 99.40% | Phase 2 | |
| HY-177578 | NN3201 | 99.15% | Phase 1 | |
| HY-P4160 | PDC31 | Inhibitor | 98.67% | Phase 1 |
Inhibitory Antibodies
(1)
| Referencia número | Nombre del producto |
Efecto
|
Pureza |
Phase |
|---|---|---|---|---|
| HY-P99016B | Enfortumab vedotin-ejfv (solution) | Inhibitor | 99.78% | Phase 3 |
Pre-clinical Phase
Bioactive Molecules
(237)
Inhibitory Antibodies
(2)
| Referencia número | Nombre del producto |
Efecto
|
Pureza |
Rare Diseases
|
|---|---|---|---|---|
| HY-164154 | ADC Control Human IgG1-vcMMAF | Inhibitor | 97.28% | Unkown |
| HY-P992332 | CIT-013 | / | Unkown |